Results 1 to 10 of about 6,690 (95)

The Use of Rifaximin in Patients With Cirrhosis [PDF]

Hepatology, 2021
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical
Caraceni, Paolo, Vargas, Victor, Solà, Elsa, Alessandria, Carlo, de Wit, Koos, Trebicka, Jonel, Angeli, Paolo, Mookerjee, Rajeshwar P, Durand, François, Pose, Elisa, Krag, Aleksander, Bajaj, Jasmohan S, Beuers, Ulrich, Ginès, Pere, LIVERHOPE Consortium, Adrià, Juanola, Laura, Napoleone, Marta, Carol, Emma, Avitabile, Ann, Ma Thu, Marta, Cervera, Martina, Pérez, Ana Belén, Rubio-Garcia, Alicia, Ardiaca, Adriana, Vives, Judit, Pich, Núria, Fabrellas, Giacomo, Zaccherini, Maria Teresa, Chiappa, César, Jiménez, Ester, Palacio, Daniela, Campion, Tommaso, Lanzillotti, Salvatore, Piano, Gea, Nicolao, Frank, Uschner, Sabine, Graf Dirmeier, Claire, Francoz, Olivier, Roux, Vanessa, Esnault, Jeltje, Helder, Marites, Aban, Konstantin, Kazankov, Marko, Korenjak, Patrick, Kamath, Juan G, Abraldes, Hugh, Watson   +46 more
openaire   +5 more sources

Rifaximin and Crohn’s disease

World Journal of Gastroenterology, 2013
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic ...
Cosimo, Prantera, Maria Lia, Scribano
openaire   +2 more sources

Rifaximin

Reactions Weekly, 2017
  +5 more sources

Bears, beets, rifaximin

Canadian Liver Journal, 2021
Peter L, Wang, Jennifer A, Flemming
openaire   +2 more sources

Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. [PDF]

Gut Microbes
Correale C, Morandi M, Gil-Gomez A, Silvestri A, Gatti A, Braga D, Maroli A, Foppa C, De Zanet S, Algieri F, Lizier M, Rossetti R, Carloni S, Penna G, Spinelli A, Brescia P, Rescigno M.   +16 more
europepmc   +1 more source

Rifaximin [PDF]

, 2020
openaire   +1 more source

Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer with rifaximin and antisense oligonucleotide. [PDF]

J Transl Med
Shuai X, Sun Y, Li J, Gao Y, Cheng Z, Liu S.   +5 more
europepmc   +1 more source

Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review. [PDF]

World J Methodol
Shah Q, Soldera J.
europepmc   +1 more source

Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses. [PDF]

Pharmacol Rep
Palenca I, Franzin SB, Pesce M, Sarnelli G, Esposito G.   +4 more
europepmc   +1 more source

The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research. [PDF]

Ann Med
Wang W, Wen Y.
europepmc   +1 more source